Business Description
CellaVision AB
ISIN : SE0000683484
Share Class Description:
CHIX:CEVIs: Bearer ShsTotal Employee Number:
253Compare
Compare
Traded in other countries / regions
CEVI.Sweden0MR5.UKC26.GermanyCLVSF.USA IPO Date
2015-10-23Description
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 10.26 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.13 | |||||
Interest Coverage | 29.18 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 10.4 | |||||
Beneish M-Score | -2.86 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.9 | |||||
3-Year EBITDA Growth Rate | 7.2 | |||||
3-Year EPS without NRI Growth Rate | 9 | |||||
3-Year FCF Growth Rate | 19 | |||||
3-Year Book Growth Rate | 11.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.96 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.69 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
12-1 Month Momentum % | -5.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 2.82 | |||||
Cash Ratio | 1.86 | |||||
Days Inventory | 181.55 | |||||
Days Sales Outstanding | 57.02 | |||||
Days Payable | 62.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.44 | |||||
3-Year Dividend Growth Rate | 7.7 | |||||
Shareholder Yield % | 2.2 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.98 | |||||
Operating Margin % | 23.74 | |||||
Net Margin % | 18.35 | |||||
EBITDA Margin % | 24.12 | |||||
FCF Margin % | 16.44 | |||||
OCF Margin % | 27.59 | |||||
ROE % | 15.54 | |||||
ROA % | 12.42 | |||||
ROIC % | 15.96 | |||||
3-Year ROIIC % | 24.77 | |||||
ROC (Joel Greenblatt) % | 71.82 | |||||
ROCE % | 18.41 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.34 | |||||
Forward PE Ratio | 26.22 | |||||
PE Ratio without NRI | 24.34 | |||||
Shiller PE Ratio | 26.37 | |||||
Price-to-Owner-Earnings | 44.19 | |||||
PEG Ratio | 2.9 | |||||
PS Ratio | 4.47 | |||||
PB Ratio | 3.57 | |||||
Price-to-Tangible-Book | 8.67 | |||||
Price-to-Free-Cash-Flow | 27.16 | |||||
Price-to-Operating-Cash-Flow | 16.19 | |||||
EV-to-EBIT | 17.22 | |||||
EV-to-Forward-EBIT | 16.4 | |||||
EV-to-EBITDA | 17.22 | |||||
EV-to-Forward-EBITDA | 13.87 | |||||
EV-to-Revenue | 4.16 | |||||
EV-to-Forward-Revenue | 4.39 | |||||
EV-to-FCF | 25.43 | |||||
Price-to-GF-Value | 0.65 | |||||
Price-to-Projected-FCF | 1.75 | |||||
Price-to-DCF (Earnings Based) | 1.41 | |||||
Price-to-DCF (FCF Based) | 2.16 | |||||
Price-to-Median-PS-Value | 0.39 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.69 | |||||
Price-to-Graham-Number | 3.06 | |||||
| Price-to-Net-Current-Asset-Value | 12.99 | |||||
| Price-to-Net-Cash | 333.75 | |||||
Earnings Yield (Greenblatt) % | 5.8 | |||||
FCF Yield % | 3.7 | |||||
Forward Rate of Return (Yacktman) % | 12.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CellaVision AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 730.592 | ||
| EPS (TTM) (kr) | 5.62 | ||
| Beta | 0.1004 | ||
| 3-Year Sharpe Ratio | -1.93 | ||
| 3-Year Sortino Ratio | -1.7 | ||
| Volatility % | 5.68 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (kr) | 0.000007 | ||
| 20-Day SMA (kr) | 160.2 | ||
| 12-1 Month Momentum % | -5.26 | ||
| 52-Week Range (kr) | 160.2 - 169.1 | ||
| Shares Outstanding (Mil) | 23.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CellaVision AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CellaVision AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 11:00 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 07:20 | In 133 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-17 11:00 | In 21 days | ||
| Second quarter earnings results for 2026 | 2026-07-17 07:20 | In 21 days | ||
| SEK 2.750000 Cash Dividend | 2026-04-29 | 160.20 (+0.00%) | ||
| General meeting for 2026 | 2026-04-28 15:00 | 160.20 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-24 11:00 | 160.20 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-24 07:20 | 160.20 (+0.00%) | ||
| Annual report for 2025 | 2026-04-01 | 160.20 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-05 11:00 | 160.20 (+0.00%) |
Show
Entries
CellaVision AB Frequently Asked Questions
What is CellaVision AB(CHIX:CEVIs)'s stock price today?
The current price of CHIX:CEVIs is kr160.20. The 52 week high of CHIX:CEVIs is kr169.10 and 52 week low is kr160.20.
When is next earnings date of CellaVision AB(CHIX:CEVIs)?
The next earnings date of CellaVision AB(CHIX:CEVIs) is 2026-07-17 Est..
Does CellaVision AB(CHIX:CEVIs) pay dividends? If so, how much?
CellaVision AB(CHIX:CEVIs) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on CellaVision AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers